The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
December 23rd 2024
The top 5 idiopathic pulmonary fibrosis (IPF) articles of 2024 explored topics like the effect of oxygen therapy on health care costs and mortality; delayed diagnoses leading to worse outcomes; new drug trials; the impact of diabetes on pulmonary health; and the growing body of research on macrophages and pulmonary fibrosis.
Dr Krystyn Van Vliet on Using Engineered 3D Platforms to Identify Potential MS Drug Candidates
March 15th 2024Krystyn Van Vliet, PhD, vice president for research and innovation at Cornell University's Meinig School of Biomedical Engineering, discusses using engineered 3D platforms to identify potential multiple sclerosis (MS) drug candidates.
Watch
FDA Approves Resmetirom, First Treatment for NASH With Liver Fibrosis
March 14th 2024The first medication for the treatment of nonalcoholic steatohepatitis (NASH) and liver fibrosis received accelerated approval. Previously, the only treatment available to patients was implementing lifestyle changes aimed at weight reduction.
Read More
Deuruxolitinib Demonstrates Efficacy, Tolerability in Patients With Moderate to Severe AA
March 14th 2024Posters suggest deuruxolitinib, a medication targeting specific cellular pathways, effectively promotes hair regrowth in patients with moderate to severe alopecia areata (AA) and results in minimal adverse events.
Read More
Disease-Free, Overall Survival Lower in Patients With CRC Treated With PE, CRS/HIPEC
March 14th 2024Patients with stage IV colorectal cancer (CRC) had lower overall and disease-free survival if they had a pelvic exenteration (PE) or cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).
Read More
Admission Heart Rate Can Be Used as an In-Hospital Mortality Risk Marker in Patients With AECOPD, RF
March 14th 2024Results demonstrated a nonlinear relationship between admission heart rate (AHR) and in-hospital mortality in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and respiratory failure (RF).
Read More
Quality of Life, Severity Scales Correlated in Patients With Psoriasis Worldwide
March 13th 2024Study findings show that scores on the Psoriasis Area and Severity Index and the Dermatology Quality of Life Index are correlated in patients with psoriasis across several continents, but factors affecting each of these scores are different across countries.
Read More
Patients With MPNs Have Increased Risk of Thrombosis, Hemorrhage, Leukemic Transformation
March 13th 2024Compared with matched controls, patients with myeloproliferative neoplasms (MPNs) had a higher risk of developing thrombosis, hemorrhage, and leukemic transformation, according to a longitudinal cohort study.
Read More
Severe Prenatal Grief May Increase Child’s Heart Failure Risk
March 12th 2024Research found that maternal loss of a partner or older child, as well as the loss of a close relative due to unnatural causes in the year before or during pregnancy, were linked to a heightened risk of heart failure in offspring.
Read More
Most private health insurers have yet to publish criteria for when they will cover postpartum depression drug, zuranolone; state lawmakers are increasingly opposing health care mergers that they believe do not serve the public interest; Medicaid extensions made in 2021 led to a 40% decline in postpartum lack of insurance.
Read More
Diagnosis and Treatment Timeline: Different Phases of Ph+ ALL Management
March 11th 2024The panel provides an overview of the various Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) treatment phases, highlighting the important discussion around inpatient versus outpatient care.
Watch
Novo Nordisk is working with authorities in several countries to tackle counterfeit versions of popular diabetes drug semaglutide (Ozempic); Amylyx’s controversial amyotrophic lateral sclerosis (ALS) drug failed to help patients in a large follow-up study; disruptions from the Change Healthcare cyberattack are costing health providers as much as $1 billion a day.
Read More
Venetoclax/Azacitidine Shows Promise for Relapse Prevention in High-Risk MDS and AML
March 9th 2024Venetoclax and azacitidine was found safe, but further randomized trials are needed to determine the full extent of the combination’s efficacy in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Read More
FDA Approves Semaglutide to Prevent Heart Events in Patients With CVD and Excess Weight
March 8th 2024The FDA added another indication for semaglutide (Wegovy), expanding its use to reduce the risk of cardiovascular death, heart attack, or stroke in adults who have cardiovascular disease (CVD) and overweight or obesity.
Read More